Literature DB >> 8627161

Selective development of T helper (Th)2 cells induced by continuous administration of low dose soluble proteins to normal and beta(2)-microglobulin-deficient BALB/c mice.

J C Guery1, F Galbiati, S Smiroldo, L Adorini.   

Abstract

Continuous administration of soluble proteins, delivered over a 10-d period by a mini-osmotic pump implanted subcutaneously, induces a long-lasting inhibition of antigen-specific T cell proliferation in lymph node cells from BALB/c mice subsequently primed with antigen in adjuvant. The decreased T cell proliferative response is associated with a down-regulation of the T helper cell (Th)1 cytokines interleukin (IL)-2 and interferon (IFN)-gamma and with a strong increase in the secretion of the Th2 cytokines IL-4 and IL-5 by antigen specific CD4+ T cells. This is accompanied by predominant inhibition of antigen-specific antibody production of IgG2a and IgG2b, rather than IgG1 isotype. Interestingly, inhibition of Th1 and priming of Th2 cells is also induced in beta(2) microglobulin-deficient BALB/c mice, indicating that neither CD8+ nor CD4+ NK1.1+ T cells, respectively, are required. The polarization in Th2 cells is stably maintained by T cell lines, all composed of CD4+/CD8- cells expressing T cell receptor for antigen (TCR) alpha/beta chains, derived from BALB/c mice treated with continuous antigen administration, indicating that they originate from Th2 cells fully differentiated in vivo. This polarization is induced in BALB/c mice by continuous administration of any protein antigen tested, including soluble extracts from pathogenic microorganisms. Priming of Th2 cells is dose dependent and it is optimal for low rather than high doses of protein. Blocking endogenous IL-4 in vivo inhibits expansion of antigen-specific Th2 cells, but does not restore IFN-gamma production by T cells from mice treated with soluble antigen-specific Th2 cells, but does not restore IFN-gamma production by T cells from mice treated with soluble antigen, indicating the involvement of two independent mechanisms. Consistent with this, Th2 cell development, but not inhibition of Th1 cells, depends on non-major histocompatibility complex genetic predisposition, since the Th2 response is amplified in BALB/c as compared to DBA/2, C3H, or C57BL/6 mice whereas tested. These findings support the hypothesis that continuous release of low amounts of protein antigens from pathogenic microorganisms may polarize the immune response toward a Th2 phenotype in susceptible mouse strains.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627161      PMCID: PMC2192465          DOI: 10.1084/jem.183.2.485

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  50 in total

1.  Aqueous antigens induce in vivo tolerance selectively in IL-2- and IFN-gamma-producing (Th1) cells.

Authors:  H J Burstein; C M Shea; A K Abbas
Journal:  J Immunol       Date:  1992-06-15       Impact factor: 5.422

2.  Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major.

Authors:  P A Bretscher; G Wei; J N Menon; H Bielefeldt-Ohmann
Journal:  Science       Date:  1992-07-24       Impact factor: 47.728

Review 3.  Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection.

Authors:  A Sher; R T Gazzinelli; I P Oswald; M Clerici; M Kullberg; E J Pearce; J A Berzofsky; T R Mosmann; S L James; H C Morse
Journal:  Immunol Rev       Date:  1992-06       Impact factor: 12.988

4.  Defining protective responses to pathogens: cytokine profiles in leprosy lesions.

Authors:  M Yamamura; K Uyemura; R J Deans; K Weinberg; T H Rea; B R Bloom; R L Modlin
Journal:  Science       Date:  1991-10-11       Impact factor: 47.728

5.  Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering.

Authors:  A Miller; O Lider; A B Roberts; M B Sporn; H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

6.  Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy.

Authors:  A Gaur; B Wiers; A Liu; J Rothbard; C G Fathman
Journal:  Science       Date:  1992-11-27       Impact factor: 47.728

7.  Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand.

Authors:  B D Evavold; P M Allen
Journal:  Science       Date:  1991-05-31       Impact factor: 47.728

8.  In vivo role of interleukin 4 in T cell tolerance induced by aqueous protein antigen.

Authors:  H J Burstein; A K Abbas
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

9.  Targeting autoantigen to B cells prevents the induction of a cell-mediated autoimmune disease in rats.

Authors:  M J Day; A G Tse; M Puklavec; S J Simmonds; D W Mason
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

10.  The injection of deaggregated gamma globulins in adult mice induces antigen-specific unresponsiveness of T helper type 1 but not type 2 lymphocytes.

Authors:  D De Wit; M Van Mechelen; M Ryelandt; A C Figueiredo; D Abramowicz; M Goldman; H Bazin; J Urbain; O Leo
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

View more
  41 in total

1.  CD4(+) Valpha14 natural killer T cells are essential for acceptance of rat islet xenografts in mice.

Authors:  Y Ikehara; Y Yasunami; S Kodama; T Maki; M Nakano; T Nakayama; M Taniguchi; S Ikeda
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

2.  Coadministration of interleukin 12 expression vector with antigen 2 cDNA enhances induction of protective immunity against Coccidioides immitis.

Authors:  C Jiang; D M Magee; R A Cox
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

3.  Requirement for natural killer T (NKT) cells in the induction of allograft tolerance.

Authors:  K I Seino; K Fukao; K Muramoto; K Yanagisawa; Y Takada; S Kakuta; Y Iwakura; L Van Kaer; K Takeda; T Nakayama; M Taniguchi; H Bashuda; H Yagita; K Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

4.  Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response.

Authors:  P J Lewis; L A Babiuk
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  Development of allergic airway disease in mice following antibiotic therapy and fungal microbiota increase: role of host genetics, antigen, and interleukin-13.

Authors:  Mairi C Noverr; Nicole R Falkowski; Rod A McDonald; Andrew N McKenzie; Gary B Huffnagle
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

6.  Th2 polarization enhanced by oral administration of higher doses of antigen.

Authors:  M Hashiguchi; S Hachimura; A Ametani; S Kaminogawa
Journal:  Cytotechnology       Date:  2000-07       Impact factor: 2.058

7.  Antigen kinetics determines immune reactivity.

Authors:  Pål Johansen; Tazio Storni; Lorna Rettig; Zhiyong Qiu; Ani Der-Sarkissian; Kent A Smith; Vania Manolova; Karl S Lang; Gabriela Senti; Beat Müllhaupt; Tilman Gerlach; Roberto F Speck; Adrian Bot; Thomas M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

Review 8.  New routes for allergen immunotherapy.

Authors:  Pål Johansen; Seraina von Moos; Deepa Mohanan; Thomas M Kündig; Gabriela Senti
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

9.  Antigen-based therapy for the treatment of type 1 diabetes.

Authors:  Jide Tian; Daniel L Kaufman
Journal:  Diabetes       Date:  2009-09       Impact factor: 9.461

10.  Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells.

Authors:  Leona Gabrysová; Kirsty S Nicolson; Heather B Streeter; Johan Verhagen; Catherine A Sabatos-Peyton; David J Morgan; David C Wraith
Journal:  J Exp Med       Date:  2009-07-27       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.